Evidence map›Paper›PMID 34993252›Full record

ArticleJournal of immunology research2021

Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.

Miaomiao Gou, Tongtong Qu, Zhikuan Wang, Huan Yan, Yanhai Si, Yong Zhang, Guanghai Dai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Miaomiao GouMedical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, China 100853.ORCID https://orcid.org/0000-0001-9622-1198
Tongtong QuMedical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, China 100853.
Zhikuan WangMedical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, China 100853.
Huan YanMedical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, China 100853.ORCID https://orcid.org/0000-0001-7966-0359
Yanhai SiMedical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, China 100853.
Yong ZhangMedical Oncology Department, The Second Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, China 100853.ORCID https://orcid.org/0000-0002-7375-7296
Guanghai DaiMedical Oncology Department, The First Medical Center, Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing, China 100853.ORCID https://orcid.org/0000-0002-7339-3840

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsBiomarkers for systemic inflammation have been introduced into clinical practice for risk-rating in cancer patients' treatment. This study is aimed at confirming the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) as an effective biomarker for patients with metastatic gastric cancer (MGC) receiving anti-PD-1 agents.

methodPatients with MGC who received anti-PD-1 treatment at the Chinese PLA General Hospital between January 2016 and November 2020 were reviewed. The study analyzed the association of NLR and overall survival (OS) or progression-free survival (PFS) and antitumor response rate with PD-1 inhibitors.

results137 patients were included in the final analysis. The area under the curve value of NLR for 6-month OS was 0.71. The best cut-off value for NLR was 3.23. NLR < 3.23 was associated with longer OS (HR = 0.38, 95% CI, 0.26-0.57,

conclusionsPretreatment elevated NLR was significantly associated with inferior PFS and OS in patients with MGC who received anti-PD-1 inhibitors. Clinicians need to consider patients with elevated NLR for decisions on immunotherapy strategy.

Indexed as

Leukocyte CountLymphocytesNeutrophilsAdultAgedBiomarkersFemaleHumansImmune Checkpoint InhibitorsLymphocyte CountMaleMiddle AgedMolecular Targeted TherapyNeoplasm StagingPrognosisProgrammed Cell Death 1 ReceptorBiomarkersImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID34993252
PMCPMC8727102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.